Prospector Partners LLC Buys Shares of 74,075 Hologic, Inc. (NASDAQ:HOLX)

Prospector Partners LLC bought a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 74,075 shares of the medical equipment provider’s stock, valued at approximately $5,293,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in HOLX. Norges Bank purchased a new stake in shares of Hologic during the 4th quarter valued at $217,529,000. Qube Research & Technologies Ltd lifted its holdings in shares of Hologic by 117.2% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider’s stock valued at $95,651,000 after purchasing an additional 743,557 shares during the last quarter. Jennison Associates LLC purchased a new stake in shares of Hologic during the 4th quarter valued at $30,079,000. Assenagon Asset Management S.A. lifted its holdings in shares of Hologic by 90.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 845,493 shares of the medical equipment provider’s stock valued at $58,677,000 after purchasing an additional 401,486 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in shares of Hologic by 8.9% during the 3rd quarter. Victory Capital Management Inc. now owns 4,838,090 shares of the medical equipment provider’s stock valued at $335,763,000 after purchasing an additional 393,371 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

HOLX stock traded down $1.11 during trading on Thursday, hitting $73.70. The stock had a trading volume of 502,895 shares, compared to its average volume of 1,686,416. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $82.45. The stock has a market capitalization of $17.20 billion, a P/E ratio of 38.17, a PEG ratio of 2.48 and a beta of 1.01. The company’s 50-day moving average price is $76.17 and its two-hundred day moving average price is $73.81.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.05. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The business’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.06 EPS. As a group, research analysts predict that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Friday, May 3rd. William Blair restated an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. UBS Group raised their target price on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research note on Friday, February 2nd. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Finally, Argus lifted their price objective on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Hologic has a consensus rating of “Moderate Buy” and an average price target of $85.60.

Insider Transactions at Hologic

In other news, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the sale, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. Insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.